
A MEDICINE COMPANY

IL-13 is a Dominant Cytokine

in the Pathophysiology of AD[1,2]

There are ***three approved biologics*** that target IL-13 signaling.[3-5]



Dupilumab[3]	Lebrikizumab-lbkz[4]	Tralokinumab-ldrm[5]
Blocks Type II receptor heterodimerization, preventing IL-13 signaling[3,6,7]	Blocks Type II receptor heterodimerization, preventing IL-13 signaling[4,8,9]	Blocks IL-13 binding to IL-13Rα1, preventing Type II receptor heterodimerization[5,9]
IL-13 can bind to the IL-13Rα2 decoy receptor[7]	IL-13 can bind to the IL-13Rα2 decoy receptor[10]	Blocks IL-13 binding with the IL-13Rα2 decoy receptor[9]
Blocks IL-4 signaling (not shown)[3,6]	Preserves IL-4 signaling (not shown)[11-13]	Preserves IL-4 signaling (not shown)[11-13]

All three therapeutic antibodies differ in their binding affinity, dissociation constant, potency, and half-life.[4,10,14-17]

To learn more about the role of IL-13 in AD, click below

Explore

Access US Prescribing Information at the following URLs:

DUPIXENT®: https://www.regeneron.com/downloads/dupixent_fpi.pdf

EBGLYSS®: https://pi.lilly.com/us/ebglyss-uspi.pdf

ADBRY®: https://www.leo-pharma.us/adbrypi

AD=atopic dermatitis; **IL**=interleukin; **IL-4Rα**=interleukin-4 receptor alpha; **IL-13Rα1**=interleukin-13 receptor alpha 1; **IL-13Rα2**=interleukin-13 receptor alpha 2.

1. Tsoi LC, et al. *J Invest Dermatol.* 2019;139(7):1480-1489. **2.** He H, et al. *J Allergy Clin Immunol.* 2021;147(1):199-212. **3.** DUPIXENT® [US PI]. Tarrytown, NY, USA: Regeneron Pharmaceuticals, Inc., 2024. **4.** EBGLYSS® [US PI] Indianapolis, IN, USA: Eli Lilly USA LLC, 2024. **5.** ADBRY® [US PI]. Madison, NJ: LEO Pharma Inc., 2024. **6.** Matsunaga K, et al. *Allergol Int.* 2020;69:187-196. **7.** Kasaian MT, et al. *J Pharmacol Exp Ther*. 2008;325:882-892. **8.** Simpson EL, et al. *J Am Acad Dermatol*. 2018;78(5):863-871.e11. **9.** Gonçalves F, et al. *Drugs Context.* 2021;10:2021-1-7. **10.** Ultsch M, et al. *J Mol Biol*. 2013;425(8). **11.** Moyle M, et al. *Exp Dermatol.* 2019;28(7):756-768. **12.** Lytvyn Y, Gooderham M. *Pharmaceutics*. 2023;15(2):568. **13.** Bieber T. *Allergy*. 2020;75(1):54-62. **14.** Okragly A, et al. *Dermatol Ther (Heidelb)*. 2023;13(7):1535-1547. **15.** Popovic B, et al. *J Mol Biol*. 2017;429(2):208-219. **16.** Adtralza [SmPC]. Ballerup, Denmark: LEO Pharma A/S, 2021. **17.** Dupixent EMA Assessment Report, 2017.

This content was commissioned by Lilly Medical and is intended to be used by HCPs for medical, scientific, and educational purposes.

Other product/company names mentioned herein are trademarks of their respective owners.
MMAT-01810 © 2026 LILLY USA, LLC. ALL RIGHTS RESERVED.